# In vitro transcription for RNA products

Source: https://onco.cc/terms/in-vitro-transcription/  
OnCo record `in-vitro-transcription` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Enzymes can copy a DNA template into RNA outside a living cell. Producing the transcript is followed by questions about its identity, composition and suitability for use.

## Summary

Experimental RNA-manufacturing studies distinguish the intended in vitro-transcribed RNA from contaminating products and test how purification affects its performance. A primary RNA-construct study then measured expression and immune stimulation after delivering transcripts to cells. RNA production, product quality and biological performance are separate observations. An RNA yield or a band of the expected size alone does not establish a released product or a clinical treatment effect.

A protocol from authors affiliated with TriLink Biotechnologies describes co-transcriptional capping with the company's CleanCap AG reagent, reported to give 94 per cent cap 1 structure at 5 mg/ml of transcription, against cap 0 products at lower efficiency from first-generation cap analogues (Henderson and colleagues). It describes one reagent and is not a release specification. Separately, T7 polymerase initiated transcription from a promoter-less DNA end and made an antisense strand that paired with the intended RNA as long double-stranded RNA, which stimulated the innate sensor MDA5; the activity was suppressed by modified nucleotides or a lower magnesium concentration (Mu and colleagues). Release analytics are layered: reviews list sequence and modification identity, poly(A) tail, RNA content by UV spectrophotometry, integrity and transcript length by gel or capillary electrophoresis or chromatography, double-stranded RNA by immunoblot or ELISA, and residual DNA as separate attributes; purification has to remove template DNA, unincorporated nucleotides and enzymes; residual nucleotides are controlled below predefined thresholds that need much lower detection limits than the main product, with the intact mRNA itself complicating their detection (Losada and colleagues; Nowak and colleagues). Because RNA content and integrity are separate assays, total mass alone does not show full-length product.

## Fields

- Kind: Term
- Last checked: 2026-11-09
- Also known as: IVT RNA production; in-vitro-transcribed RNA

## Notes

- In vitro transcription copies a DNA template into RNA outside living cells. A T7 promoter recruits the transcription machinery; a Kozak context acts at translation initiation. Cap addition during transcription or afterwards, and template-encoded or enzyme-added poly(A), are distinct process choices. The DNA is a manufacturing input; residual DNA in the product is a separate quality attribute. Preserve the connection from the intended antigen sequence through the finished construct and its expression and potency tests.
- NEB's IVT evaluation protocol says unincorporated nucleotides and template DNA affect the 260-nanometre absorbance reading and calls for their removal before RNA quantification. This is vendor analytical guidance, not a clinical specification. Record purification and the quantification method separately from transcript length and integrity; total mass alone does not identify full-length RNA.

## Sources

- Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.: https://doi.org/10.1093/nar/gkr695
- A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA.: https://doi.org/10.1016/j.omtn.2019.02.018
- Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.: https://doi.org/10.1182/blood-2006-04-015024
- Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap® Analog by In Vitro Transcription.: https://doi.org/10.1002/cpz1.39
- An origin of the immunogenicity of in vitro transcribed RNA.: https://doi.org/10.1093/nar/gky177
- From nucleotides to intact transcripts through oligonucleotides: Integrated chromatographic strategies for therapeutic mRNA characterization.: https://doi.org/10.1007/s00216-026-06615-x
- Process and analytical strategies for the safe production of mRNA vaccines and therapeutics.: https://doi.org/10.1007/s11033-026-11455-0
- NEB: Evaluation of IVT Reaction Products, analytical protocol: https://www.neb.com/en-us/protocols/evaluation-of-ivt-reaction-products?pdf=true

## Connected records

- terms: [Chemistry, manufacturing and controls](https://onco.cc/terms/chemistry-manufacturing-controls/), [Codon optimization](https://onco.cc/terms/codon-optimization/), [Double-stranded RNA impurities](https://onco.cc/terms/dsrna-impurities/), [Immune measurements and product evidence](https://onco.cc/terms/immune-product-evidence/), [Messenger RNA construct anatomy](https://onco.cc/terms/mrna-construct-anatomy/)
- technologies: [Plasmid DNA and mRNA raw-material manufacturing](https://onco.cc/technologies/plasmid-dna-manufacturing/)

---
JSON: https://onco.cc/api/v1/entities/in-vitro-transcription.json